Health and Healthcare

BioHealth Business Daily (AMGN, NVS, AMLN, LLY, ALKS, NVO, LLY, VICL, SCLN, ARNA)

These are some of the top stories affecting key drug and biotech stocks that are covered with more in-depth details and analysis this morning at BioHealthInvestor.com:

Amgen Inc’s (Nasdaq: AMGN)’s osteoporosis drug did so well in a head-to-head Phase III trial vs. the current standard drug from Novartis Inc. (NYSE:  NVS) that the Amgen’s drug may become the new standard for patients with breast cancer.

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), along with partners Eli Lilly & Co. (NYSE: LLY) and Alkermes Inc. (Nasdaq: ALKS), announced its new drug application for a once-weekly version of Byetta will be reviewed by the FDA, which may  help invigorate growth for the franchise.

Vical Inc. (Nasdaq: VICL) announced a positive four-month interim analysis for what is arguably its second-largest market opportunity, taking potentially another small step toward the goal of attracting a partner for its herpes vaccine program.

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) shares are down more than 7 percent on revenue and secondary offering fears. And Arena Pharmaceuticals Inc. (Nasdaq: ARNA) shares are falling after another dilutive offering.

Also, see our in-depth feature this week on five of the fastest-growing biotechs with improving analyst estimates: Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), Amicus Therapeutics Inc. (Nasdaq: FOLD), Halozyme Therapeutics Inc. (Nasdaq: HALO), American Oriental Bioengineering Inc. (NYSE: AOB), and Stemcells Inc. (Nasdaq: STEM).

-The 24/7 Wall St. Team

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.